{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T04:14:46Z","timestamp":1771042486439,"version":"3.50.1"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1603,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1111\/j.1439-0507.2009.01803.x","type":"journal-article","created":{"date-parts":[[2009,11,3]],"date-time":"2009-11-03T14:25:08Z","timestamp":1257258308000},"page":"230-233","source":"Crossref","is-referenced-by-count":6,"title":["Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients"],"prefix":"10.1111","volume":"54","author":[{"given":"Maria J. G. T.","family":"R\u00fcping","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg J.","family":"Vehreschild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika","family":"B\u00f6hme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Mousset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urs","family":"Harnischmacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Frommolt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gernot","family":"Wassmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivonne","family":"Drzisga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hallek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,4,12]]},"reference":[{"key":"10.1111\/j.1439-0507.2009.01803.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.2165\/00003495-200767110-00004","article-title":"Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients","volume":"67","author":"Maschmeyer","year":"2007","journal-title":"Drugs"},{"key":"10.1111\/j.1439-0507.2009.01803.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1128\/CMR.00029-06","article-title":"Epidemiology of invasive candidiasis: a persistent public health problem","volume":"20","author":"Pfaller","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"10.1111\/j.1439-0507.2009.01803.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0140-6736(05)67490-9","article-title":"Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial","volume":"366","author":"Kullberg","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1439-0507.2009.01803.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1439-0507.2009.01803.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1128\/AAC.01388-07","article-title":"Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients","volume":"52","author":"Troke","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1439-0507.2009.01803.x-BIB6|cit6","first-page":"1165","article-title":"Update on the treatment of disseminated fusariosis: focus on voriconazole","volume":"3","author":"Stanzani","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"10.1111\/j.1439-0507.2009.01803.x-BIB7|cit7","volume-title":"ASH Annual Meeting","author":"Wingard","year":"2007"},{"key":"10.1111\/j.1439-0507.2009.01803.x-BIB8|cit8","unstructured":"ClinicalTrials.gov Voriconazole versus itraconazole in primary prophylaxis of invasive fungal infection (IFI) in subjects with allogeneic hematopoietic stem cell transplants (HSCT) [WWW document] 2008 http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00289991?term=itraconazole&rank=17"},{"key":"10.1111\/j.1439-0507.2009.01803.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1439-0507.2009.01803.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/FTD.0b013e318167d0e0","article-title":"Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations","volume":"30","author":"Smith","year":"2008","journal-title":"Ther Drug Monit"},{"key":"10.1111\/j.1439-0507.2009.01803.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1345\/aph.1L243","article-title":"Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis","volume":"42","author":"Howard","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1111\/j.1439-0507.2009.01803.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jinf.2007.07.003","article-title":"A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML)","volume":"55","author":"Vehreschild","year":"2007","journal-title":"J Infect"},{"key":"10.1111\/j.1439-0507.2009.01803.x-BIB13|cit13","unstructured":"Agilent-Technologies Informatics & software [WWW document] 2008 http:\/\/www.chem.agilent.com\/en-us\/products\/software\/pages\/default.aspx"},{"key":"10.1111\/j.1439-0507.2009.01803.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1111\/j.1439-0507.2009.01803.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1128\/AAC.48.6.2166-2172.2004","article-title":"Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration","volume":"48","author":"Walsh","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1439-0507.2009.01803.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1086\/367933","article-title":"Voriconazole: a new triazole antifungal agent","volume":"36","author":"Johnson","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1439-0507.2009.01803.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1124\/dmd.31.5.540","article-title":"Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole","volume":"31","author":"Hyland","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1111\/j.1439-0507.2009.01803.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1128\/AAC.01263-06","article-title":"Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tablets","volume":"51","author":"Dodds Ashley","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1439-0507.2009.01803.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.bmt.1705754","article-title":"Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole","volume":"40","author":"Trifilio","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1111\/j.1439-0507.2009.01803.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.46.8.2546-2553.2002","article-title":"Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens","volume":"46","author":"Purkins","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 1","key":"10.1111\/j.1439-0507.2009.01803.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1365-2125.2003.01993.x","article-title":"Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1439-0507.2009.01803.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1002\/cncr.22568","article-title":"Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients","volume":"109","author":"Trifilio","year":"2007","journal-title":"Cancer"},{"key":"10.1111\/j.1439-0507.2009.01803.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.50.5.1878-1880.2006","article-title":"Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen","volume":"50","author":"Capitano","year":"2006","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Mycoses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1439-0507.2009.01803.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1439-0507.2009.01803.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T04:12:47Z","timestamp":1625631167000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1439-0507.2009.01803.x"}},"subtitle":["Voriconazole serum concentrations in AML patients"],"short-title":[],"issued":{"date-parts":[[2011,4,12]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,5]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1439-0507.2009.01803.x","relation":{},"ISSN":["0933-7407"],"issn-type":[{"value":"0933-7407","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4,12]]}}}